Trial Profile
Acetyl-l-carnitine reduces depression and improves quality of life in patients with minimal hepatic encephalopathy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Jun 2011
Price :
$35
*
At a glance
- Drugs Levacecarnine (Primary)
- Indications Major depressive disorder
- Focus Pharmacodynamics
- 18 Jun 2011 New trial record